Carol Suh

Partner

2021

Board Member: Orbital Therapeutics, Human Immunology Biosciences (acquired by Biogen in 2024 for up to $1.8B) Board Observer: Kisbee Therapeutics (2021-Present), Remix Therapeutics (2021-Present), Resonance Medicine (2021-2023), Sesh Therapy (2021-2023), Locana Bio (2020-2024), CERo Therapeutics (2020-2022), Metacrine (2019-2020),

Principal

2019 - 2021

Senior Associate

2018 - 2019

Consultant/Intern

2018 - 2018

Co-Founder and Chief Strategy Officer

2025

Co-Founder and Chief Operating Officer

2023 - 2025

Co-Founder and SVP, Strategy

2022 - 2023

Co-founder and VP, Business Development

2019 - 2021

Co-founder, Board Member

2022

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. The company is leveraging its first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics.

Board Member of CODA (Complex Disorders Alliance)

2021

CODA is an innovative, patient-founded, patient-focused, nonprofit organization with a mission to accelerate data-driven research for complex disorders. Formerly known as Metrodora Foundation.

Board Member

2021 - 2024

Human Immunology Biosciences, Inc. (HI-Bio™), was incubated by ARCH Venture Partners and Monograph Capital to develop precision therapies for immune-mediated diseases and to bring clinical immunology into its next chapter. Acquired by Biogen for up to $1.8B. https://investors.biogen.com/news-releases/news-release-details/biogen-bolsters-late-stage-pipeline-expands-immunology-portfolio

Associate Director of Corporate Development

2019 - 2019

ARCH Venture Partners company build. Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients.

Business Development and Corporate Strategy Associate; Launch Fellow

2016 - 2017

Business Development and Corporate Strategy Associate (Jun 2017-Sept 2017) Launch Fellow (May 2016-Aug 2016): Helped prepare Magenta Therapeutics for launch and $48.5M Series A, working with Third Rock Ventures and Atlas Venture.

Senior Associate Consultant

2015 - 2016

Senior Associate Consultant (2016) Associate Consultant (2015)

R&D Strategy; Innovation Fellow

2014 - 2014

The Regenerative Medicine Discovery Performance Unit built a portfolio of innovative stem cell and regenerative medicines through in-house R&D, strategic alliances, and in-licensing opportunities.